(Hypertension. 1999;33:554-558.)
© 1999 American Heart Association, Inc.
Scientific Contribution |
Correspondence to Dr Stephen J Cleland, Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, Scotland, UK. E-mail scleland{at}clinmed.gla.ac.uk
| Abstract |
|---|
|
|
|---|
Key Words: insulin resistance endothelial function forearm blood flow human study euglycemic clamp plethysmography
| Introduction |
|---|
|
|
|---|
Recently, the concept of crosstalk between insulin's vascular and metabolic actions has been emerging.10 Specifically, it is proposed that insulin may redirect nutrient blood flow to nutritive capillary beds in skeletal muscle. Given that insulin largely appears to be an endothelium-dependent vasodilator,11 12 it seems likely that this linkage between glucose metabolism and blood flow distribution occurs at an endothelial level. Indeed, there is considerable in vitro evidence demonstrating interactions between insulin and nitric oxide synthase,13 14 15 as well as emerging evidence that metabolic and vascular control pathways interact in other tissues.16 17 However, physiological studies in humans in relation to insulin and regulation of blood flow have been less clear; although some studies have demonstrated a relationship between insulin resistance and endothelial dysfunction,18 19 others have not.20 In addition, there is considerable doubt concerning whether insulin sensitivity and insulin-mediated vasodilation are functionally associated.20 21 22 Those studies that have shown a relationship23 24 have used higher doses of insulin and the results are thus of questionable physiological significance.
We hypothesized that the discrepancy between in vitro and in vivo data on the relevance of insulin-mediated vasodilation to insulin-mediated glucose uptake might be attributable to the confounding effect of sympathetic nervous system activation during systemic hyperinsulinemia.25 26 In this setting, local vasodilator effects are likely to be influenced by centrally mediated mechanisms. Although these effects are physiologically relevant, we chose to examine forearm responses to local intrabrachial insulin infusions to focus on local actions of the hormone. Until recently, local insulin infusions were thought to have either no effect on limb blood flow27 28 29 or only a very weak influence.30 31 However, we have demonstrated in humans that forearm vasodilation during local physiological insulin infusions is significantly augmented by co-infusion of intra-arterial D-glucose.32 This was not simply an osmotic effect because co-infusing L-glucose had no effect.32 This result led us to hypothesize that insulin-stimulated tissue glucose uptake is a determinant of insulin-mediated vasodilation. In the present study, we set out to examine the relationship at physiological insulin concentrations between local insulin/glucose forearm vasodilation and whole-body glucose uptake during systemic hyperinsulinemia.
| Methods |
|---|
|
|
|---|
| Clinical Procedures |
|---|
|
|
|---|
Measurement of Insulin-Mediated Vasodilation
Forearm blood flow was measured by venous occlusion
plethysmography with electrically calibrated mercury-in-silicone
elastomer (Silastic) strain gauges (Hokanson set, PMS
instruments).34 A 27-gauge unmounted steel needle
(Cooper's Needleworks) was inserted under local anesthesia
into the brachial artery of the nondominant arm for infusions. A venous
catheter was positioned retrogradely in an antecubital vein to enable
half-hourly blood sampling for insulin, glucose, and potassium levels.
Temperature was maintained at 24 to 26°C. Blood flow was recorded
in both forearms during 3-minute periods of wrist cuff inflation at
10-minute intervals; each measurement was the mean of 5 sequential
recordings.
After baseline readings had been obtained, subjects received an intra-arterial infusion of low-dose D-glucose (75 µmol/min) for 120 minutes to maintain local venous euglycemia in the forearm vascular bed. After 30 minutes, and for the remaining 90 minutes, soluble human insulin (Actrapid, Novo Nordisk) was co-infused at a dose of 36 pmol/min. This solution was prepared in the sterile unit of the hospital pharmacy with use of glass syringes and bottles, and diluted (with saline and 4 mL of the subject's blood, 8% vol/vol) at the bedside immediately before each study (mean recovery of insulin was 95%; data not shown). In a previous study, we demonstrated that deep venous glucose levels in the contralateral arm were unchanged by this dose of insulin, confirming that there is unlikely to be any significant systemic action of insulin.32 A uniform infusion rate (2 mL/min) was used throughout the study.
Statistical Evaluation
For the forearm plethysmography data, percentage change from
basal values in the ratio of blood flow between infused and noninfused
arms was calculated, with the blood flow in the noninfused arm as a
concurrent control.34 To avoid multiple comparisons, a
summary measure was calculated which was the mean value of the last 3
readings (100 to 120 minutes).35 Data were initially
examined by simple correlation. If data were
nonparametrically distributed, the rank correlation
coefficient was calculated. Multiple regression analysis
(Minitab for Windows, Minitab Inc.) was performed to examine potential
confounders. Insulin sensitivity, age, and MAP data were normally
distributed; insulin vasodilation and BMI data were
nonparametrically distributed and were therefore
logarithmically transformed before analysis. After
identification of the best subsets in the initial model,
parameters were added in a forward stepwise fashion.
| Results |
|---|
|
|
|---|
Insulin Concentrations
During the euglycemic clamps, systemic insulin
concentrations were raised to 617±99.7 pmol/L
during the last hour. During the local insulin infusions, insulin
levels in the forearm vascular bed were raised to 782±279.8 pmol/L
during the last hour.
Whole-Body Insulin Sensitivity
M-value (mean±SD) for the group was 10.0±2.2 mg ·
kg-1 · min-1
(range, 6.8 to 14.7).
Local Insulin/Glucose-Mediated Vasodilation
Percentage change in forearm blood flow ratio (%FBFR) for the
group (median, interquartile range) was 28.2% (13.6, 48.6).
Univariate Analysis
Depending on the distribution of the data, simple (r)
or rank correlation (rs) analysis
was performed. M value was significantly correlated with %FBFR
(rs=0.60, P<0.05)
(Figure
), but not with BMI
(rs=-0.42, P<0.1), age
(r=-0.39, P<0.2), or MAP (r=0.13,
P>0.2). %FBFR was not significantly correlated with BMI
(rs=-0.15), age
(rs=0.16), or MAP
(rs=0.15) (P>0.2).
|
Multiple Regression Analysis
The Table
displays adjusted
R2 and t for %FBFR as a
predictor of M value, with forward stepwise addition of BMI, age, and
MAP. %FBFR remained a significant independent predictor of M value
after these potentially confounding variables were included in the
model (R2 [adj]=0.48,
t=3.23, P<0.01).
|
| Discussion |
|---|
|
|
|---|
Baron et al23 have previously demonstrated a significant relationship between whole-body insulin sensitivity and leg vasodilation during systemic hyperinsulinemia in healthy subjects. However, Yki-Jarvinen et al,21 although conceding that endothelial function is a significant determinant of insulin-mediated vasodilation, were unable to demonstrate a relationship between insulin sensitivity and forearm vasodilation in response to systemic hyperinsulinemia.20 21 In support of this conclusion, this group used positron emission tomography (PET) and [18F]fluoro-2-deoxy-D-glucose uptake to demonstrate a dissociation of insulin-stimulated blood flow and glucose uptake in thigh skeletal muscle. Despite this finding, however, the same study demonstrated a significant relationship between insulin-induced leg vasodilation and whole-body insulin sensitivity during systemic hyperinsulinemia,22 and the overall conclusion from these studies remains uncertain. In a more recent study in which higher resolution methods were used, the same group was able to detect co-localization of insulin-stimulated muscle blood flow with regional glucose uptake, consistent with redirection of flow to areas where insulin stimulates glucose uptake.36 Our data, which demonstrate a close correlation between direct insulin/glucose-induced arterial vasodilation and whole-body insulin-stimulated glucose uptake, also support this hypothesis.
We have observed that local insulin-mediated vasodilation is significantly augmented by co-infusion of D-glucose and have hypothesized that insulin-stimulated glucose uptake may determine muscle blood flow via crosstalk with nitric oxide pathways at an endothelial level. For example, an increase in ATP production caused by aerobic glycolysis could activate membrane ion pumps (for example Na+-K+ ATPase) resulting in hyperpolarization and changes in Ca2+ fluxes in both endothelium and vascular smooth muscle cells.37 In support of this notion we, and others, have recently shown that insulin-mediated vasodilation can be inhibited by ouabain, an inhibitor of Na+-K+ ATPase.38 39 Furthermore, clamping glucose at 20 mmol/L during systemic hyperinsulinemia (and hence increasing tissue glucose uptake) causes 50% augmentation of insulin-stimulated blood flow in humans.40
Several in vitro studies provide additional evidence that glucose uptake may be important in determining vascular smooth muscle cell relaxation.13 14 41 Of particular note is a study demonstrating nitric oxide production secondary to insulin stimulation in endothelial cell culture and subsequent blocking of this in the presence of an inhibitor of phosphatidyl inositol 3-kinase.15 The delayed time course of insulin-mediated vasodilation would also support this hypothesis: the vasodilator effect of the hormone is only evident after 30 to 40 minutes, consistent with primary effects to increase glucose uptake and metabolism. One pathophysiological implication of this hypothesis would be that a primary derangement of insulin-mediated glucose uptake would lead to reduced insulin-mediated vasodilation (and, possibly, effects on other aspects of vascular endothelial function), so providing a mechanism for vascular dysfunction in insulin-resistant subjects. The absence of a change in blood flow during a systemic infusion of fructose42 could be cited as an argument against this hypothesis, but does not rule out the possibility that the coupling signal for promotion of blood flow is unique to intracellular glucose metabolism.
The alternative physiological hypothesis, originally advanced by Baron, is that insulin-mediated vasodilation promotes insulin-mediated glucose uptake. This has the pathophysiological corollary that endothelial dysfunction, resulting in a relative inability of mediators including insulin to stimulate muscle blood flow, could account for resistance to insulin-mediated glucose uptake in some disorders.43 However, this hypothesis assumes that substrate delivery can be rate-limiting for glucose disposal, which may only be the case at supraphysiological insulin levels maintained for many hours. Results of studies in which glucose uptake has been measured during hyperinsulinemia and manipulation of limb blood flow are conflicting. For example, it has been reported that infusion of NG-monomethyl-L-arginine (L-NMMA) into the femoral artery during hyperinsulinemic euglycemia reduces insulin-mediated stimulation of blood flow (via inhibition of endothelial nitric oxide production) and decreases limb glucose uptake by 25% (despite a 50% increase in arteriovenous fractional glucose extraction).23 However, other investigations have failed to support the notion that tissue glucose uptake is dependent on skeletal muscle blood flow.44 45 46 Dissociation of insulin-mediated glucose uptake from blood flow was observed in a study in which both limb blood flow and muscle sympathetic nerve activity were stimulated to similar degrees at different systemic insulin concentrations, ranging from 100 to 400 pmol/L.25 In addition, augmentation of forearm blood flow by 100% with use of intra-arterial adenosine47 and bradykinin48 has no detectable effect on forearm glucose uptake. However, it has been argued that these vasodilators (in contrast to insulin) may not recruit areas of tissue that were previously involved in predominantly anaerobic metabolism.24
Because correlation is not proof of causality, the possibility remains that insulin's metabolic and vascular actions are not causally related in either direction but are influenced by a third factor. For example, obesity could impair insulin-mediated glucose uptake and vascular endothelial function by two separate mechanisms. It has been shown that obese insulin-resistant subjects are characterized by endothelial dysfunction and resistance to endothelium-dependent insulin-mediated vasodilation, and that there is no difference in these variables in a group of patients with NIDDM, matched for age and BMI.19 These results suggest that obesity may play a primary role in the link between insulin resistance and endothelial dysfunction, and it may help to explain why results obtained in obese NIDDM and hypertensive patient groups cannot necessarily be extrapolated to patients with a normal BMI. However, the relationship between insulin-mediated vasodilation and glucose uptake was not confounded by BMI in the current study.
In summary, we report in healthy male volunteers a significant functional relationship between insulin sensitivity and local insulin-mediated vasodilation in an experimental setting that avoids the confounding hemodynamic effects of systemic hyperinsulinemia. Further mechanistic studies are required to tease out the nature of the crosstalk between insulin signaling, glucose transport, and the endothelial nitric oxide pathway. These studies may elucidate the relationship between insulin resistance and endothelial dysfunction in the early stages of cardiovascular and metabolic disorders before the development of complications.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received September 16, 1998; first decision October 14, 1998; accepted October 26, 1998.
| References |
|---|
|
|
|---|
2. Yki-Jarvinen H, Koivisto VA. Effect of body composition on insulin sensitivity. Diabetes. 1983;32:965969.[Abstract]
3. De Fronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM; a balanced overview. Diabetes Care. 1992;15:316368.
4. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350357.[Abstract]
5.
Swan JW, Walton C, Godsland IF, Clark AL, Coats AJS,
Oliver MF. Insulin resistance in chronic heart failure. Eur
Heart J. 1994;15:15281532.
6. Williams SB, Cusco JA, Roddy M, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567574.[Abstract]
7. Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens. 1992;10:10251031.[Medline] [Order article via Infotrieve]
8.
Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of
endothelium-derived nitric oxide in the abnormal
endothelium-dependent vascular relaxation of patients
with essential hypertension. Circulation. 1993;87:14681474.
9. Drexler H, Hayoz D, Munzel T, Just H, Zelis R, Brunner HR. Endothelial function in congestive heart failure. Am Heart J. 1993;126(suppl II):761764.
10.
Clark MG, Colquhoun EQ, Rattigan S, Dora KA. Eldershaw
TPD, Hall JL, Ye J. Vascular and endocrine control of muscle
metabolism. Am J Physiol. 1995;268:E797E812.
11. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 1994;94:25112515.
12. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:11721179.
13. Graier WF, Wascher TC, Lackener L, Tplak H, Krejs GJ, Kukovetz WR. Exposure to elevated D-glucose concentrations modulates vascular endothelial cell vasodilatory response. Diabetes. 1993;42:14971505.[Abstract]
14.
Sobrevia L, Nadal A, Yudilevich DL, Mann GE. Activation
of L-arginine transport (system y+) and nitric
oxide synthase by elevated glucose and insulin in human
endothelial cells. J Physiol. 1996;490:775781.
15. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. J Clin Invest. 1996;98:894898.[Medline] [Order article via Infotrieve]
16.
Velloso LA, Folli F, Sun XJ, White MF, Saad MJA, Kahn
CR. Cross-talk between the insulin and angiotensin
signaling systems. Proc Natl Acad Sci
U S A. 1996;93:1249012495.
17. Young ME, Leighton B. Evidence for altered sensitivity of the nitric oxide/cGMP signalling cascade in insulin-resistant skeletal muscle. Biochem J. 1998;329:7339.
18.
Petrie J, Ueda S, Webb DJ, Elliott HL, Connell JMC.
Endothelial nitric oxide production and insulin
sensitivity: a physiological link with implications
for pathogenesis of cardiovascular disease.
Circulation. 1996;93:13311333.
19. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest. 1996;97:26012610.[Medline] [Order article via Infotrieve]
20. Utriainen TR, Makimattila S, Virkamaki A, Bergholm R, Yki-Jarvinen H. Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia. 1996;39:14771482.[Medline] [Order article via Infotrieve]
21. Utriainen T, Makimattila S, Virkamaki A, Lindholm H, Sovijarvi A, Yki-Jarvinen H. Physical fitness and endothelial function (nitric oxide synthesis) are independent determinants of insulin-stimulated blood flow in man. J Clin Endocrinol Metab. 1996;81:42584263.[Abstract]
22. Raitakari M, Nuutila P, Ruotsalainen U, Laine H, Teras M, Iida H, Makimattila S, Utriainen T, Oikonen V, Sipila H, Haaparanta M, Solin O, Wegelius U, Knuuti J, Yki-Jarvinen H. Evidence for dissociation of insulin stimulation of blood flow and glucose uptake in human skeletal muscle. Diabetes. 1996;45:14711477.[Abstract]
23. Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 1995;96:786792.
24.
Bonadonna RC, Saccomani MP, Del Prato S, Bonora E,
DeFronzo RA, Cobelli C. Role of tissue-specific blood flow and tissue
recruitment in insulin-mediated glucose uptake of human skeletal
muscle. Circulation. 1998;98:234241.
25. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:22462252.
26.
Muscelli E, Emdin M, Natali A, Pratali L, Camastra S,
Gastaldelli A, Baldi S, Carpeggiani C, Ferrannini E. Autonomic and
hemodynamic responses to insulin in lean and obese
humans. J Clin Endocrinol Metab. 1998;83:20842090.
27.
Creager MA, Liang C, Coffman JD. Beta
adrenergic-mediated vasodilator response to insulin in the human
forearm. J Pharmacol Exp Ther. 1985;235:709714.
28.
Natali A, Santoro D, Palombo C, Cerri M, Ghione S,
Ferrannini E. Impaired insulin action on skeletal muscle
metabolism in essential hypertension.
Hypertension. 1991;17:170178.
29.
Sakai K, Imaizumi T, Masaki H, Takeshita A.
Intra-arterial infusion of insulin attenuates
vasoreactivity in human forearm. Hypertension. 1993;22:6773.
30.
Neahring JM, Stepniakowski K, Greene AS, Egan BM.
Insulin does not reduce forearm
-vasoreactivity in obese
hypertensive or lean normotensive men. Hypertension. 1993;22:584590.
31.
Tack CJ, Lutterman JA, Vervoort G, Thien T, Smits P.
Activation of the sodium-potassium pump contributes to insulin-induced
vasodilation in humans. Hypertension. 1996;28:426432.
32.
Ueda S, Petrie JR, Cleland SJ, Elliott HL, Connell JMC.
Insulin-mediated vasodilatation is dependent on local glucose uptake: a
double-blind, placebo-controlled study. J Clin Endocrinol
Metab. 1998;83:21262131.
33.
Defronzo RA, Tobin JD, Andres R. Glucose clamp
technique: a method for quantifying insulin secretion and resistance.
Am J Physiol. 1979;237:E214E223.
34.
Benjamin N, Calver A, Collier J, Robinson B, Vallance
P, Webb D. Measuring forearm blood flow and interpreting the responses
to drugs and mediators. Hypertension. 1995;25:918923.
35. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300:230235.
36. Utriainen T, Nuutila P, Takala T, Vicini P, Ruotsalainen U, Ronnemaa T, Tolvanen T, Raitakari M, Haaparanta M, Kirvela O, Cobelli C, Yki-Jarvinen H. Intact insulin stimulation of skeletal muscle blood flow, its heterogeneity and redistribution, but not of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Invest. 1997;100:777785.[Medline] [Order article via Infotrieve]
37. Sowers JR. Effects of insulin and IGF-1 on vascular smooth muscle glucose and cation metabolism. Diabetes. 1996;45(suppl 3):S47S51.
38. Ueda S, Petrie JR, Cleland SJ, Elliott HL, Connell JMC. Insulin vasodilatation is mediated by both NO and Na+-K+ ATPase. J Hypertens. 1997;15(suppl 4):S71. Abstract.
39. Tack CJ, Lutterman JA, Vervoort G, Thien T, Smits P. Activation of the sodium-potassium pump contributes to insulin-induced vasodilation in humans. Hypertension. 1996;28:426432.
40. Baron AD. Cardiovascular actions of insulin in humans. Implications for insulin sensitivity and vascular tone. Bailliere's Clin Endocrinol Metab. 1993;7:961987.[Medline] [Order article via Infotrieve]
41.
Kahn AM, Lichtenberg RA, Allen JC, Seidel CL, Song T.
Insulin-stimulated glucose transport inhibits
Ca2+ influx and contraction in vascular smooth
muscle. Circulation. 1995;92:15971603.
42. Vollenweider P, Tappy L, Randin D, Schneiter P, Jequier E, Nicod P, Scherrer U. Differential effects of hyperinsulinaemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest. 1993;92:147154.
43.
Baron A. Hemodynamic actions of
insulin. Am J Physiol. 1994;267:E187E202.
44. Yki-Jarvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia. 1995;38:13781388.[Medline] [Order article via Infotrieve]
45. Mijares AH, Jensen MD. Contribution of blood flow to leg glucose uptake during a mixed meal. Diabetes. 1995;44:11651169.[Abstract]
46. Kelly D, Mitrakou A, Marsh H, Schwenk F, Benn J, Sonnenberg G, Arcangeli M, Aoki T, Sorensel J, Berger M, Sonksen P, Gerich J. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J Clin Invest. 1988;81:15631571.
47. Natali A, Bonadonna R, Santoro D, Galvan AQ, Baldi S, Frascerra S, Palombo C, Ghione S, Ferrannini E. Insulin resistance and vasodilation in essential hypertension: studies with adenosine. J Clin Invest. 1994;94:15701576.
48. Nuutila P, Raitakari M, Laine H, Kirvela O, Takala T, Utriainen T, Makimattila S, Pitkanen O, Ruotsalainen U, Lida H, Knuuti J, Yki-Jarvinen H. Role of blood flow in regulating insulin-stimulated glucose uptake in humans: studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography. J Clin Invest. 1996;97:17411747.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
F. Bourgoin, H. Bachelard, M. Badeau, S. Melancon, M. Pitre, R. Lariviere, and A. Nadeau Endothelial and vascular dysfunctions and insulin resistance in rats fed a high-fat, high-sucrose diet Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1044 - H1055. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lteif, P. Vaishnava, A. D. Baron, and K. J. Mather Endothelin Limits Insulin Action in Obese/Insulin-Resistant Humans Diabetes, March 1, 2007; 56(3): 728 - 734. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Levesque, M. Santure, M. Pitre, A. Nadeau, and H. Bachelard Cholinergic Involvement in Vascular and Glucoregulatory Actions of Insulin in Rats Diabetes, February 1, 2006; 55(2): 398 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Perry, A. Spiers, S. J. Cleland, G. D. O. Lowe, J. R. Petrie, and J. M. C. Connell Glucocorticoids and Insulin Sensitivity: Dissociation of Insulin's Metabolic and Vascular Actions J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 6008 - 6014. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Serne, R. G. IJzerman, R. O.B. Gans, R. Nijveldt, G. de Vries, R. Evertz, A. J.M. Donker, and C. D.A. Stehouwer Direct Evidence for Insulin-Induced Capillary Recruitment in Skin of Healthy Subjects During Physiological Hyperinsulinemia Diabetes, May 1, 2002; 51(5): 1515 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kimura, A.-M. Jefferis, H. Watanabe, and J. Chin-Dusting Insulin Inhibits Acetylcholine Responses in Rat Isolated Mesenteric Arteries via a Non-Nitric Oxide Nonprostanoid Pathway Hypertension, January 1, 2002; 39(1): 35 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Mather, S. Verma, and T. J. Anderson Improved endothelial function with metformin in type 2 diabetes mellitus J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1344 - 1350. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H Serne, R. O.B Gans, J. C ter Maaten, P. M ter Wee, A. J.M Donker, and C. D.A Stehouwer Capillary recruitment is impaired in essential hypertension and relates to insulin's metabolic and vascular actions Cardiovasc Res, January 1, 2001; 49(1): 161 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mather, M. Laakso, S. Edelman, G. Hook, and A. Baron Evidence for physiological coupling of insulin-mediated glucose metabolism and limb blood flow Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1264 - E1270. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |